Actavis to buy Forest for $25 billion; windfall for investor Icahn

[Reuters] – (Reuters) – Generic drugmaker Actavis Plc (ACT.N) said on Tuesday it would buy Forest Laboratories Inc (FRX) for about $25 billion in cash and stock, expanding its portfolio of specialty pharmaceuticals for neurological and other disorders. T more

View todays social media effects on ACT

View the latest stocks trending across Twitter. Click to view dashboard

See who Actavis is hiring next, click here to view